SHAREHOLDER ALERT: Levi & Korsinsky Notifies Investors With

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Investors With Losses on Their Investment in Family Dollar Stores, Inc. of Class Action Lawsuit and the Deadline of April 22, 2013 to Seek a Lead Plaintiff Position

NEW YORK, NY--(Marketwired - Apr 4, 2013) - Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the Western District of North Carolina on behalf of investors who purchased Family Dollar Stores, Inc. ("Family Dollar" or the "Company") ( NYSE : FDO ) stock between October 3, 2012 and January 2, 2013.

For more information, click here: http://zlk.9nl.com/family-dollar-fdo/ . 

The complaint alleges that during the Class Period, defendants issued materially false and misleading statements regarding Family Dollar's then-present sales demand, profitability and financial results for the first quarter of 2013 and for December 2012. As a result of defendants' false statements, Family Dollar's stock traded at artificially inflated prices throughout the Class Period, reaching a high of $71.20 per share by November 30, 2012. It is further alleged that during this time Family Dollar's senior executives cashed in, selling their own Family Dollar stock at artificially inflated prices; during the Class Period the Company's Chief Executive Officer sold more than $15.6 million worth of his Family Dollar stock.

On January 3, 2013, Family Dollar issued a press release disclosing that sales in the Company's first quarter 2013 had significantly underperformed and that the Company was slashing 2013 financial guidance. Upon this news, Family Dollar stock fell $8.30 per share to close at $55.74 on January 3, 2012.

If you suffered a loss in Family Dollar you have until April 22, 2013 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (877) 363-5972, or visit http://zlk.9nl.com/family-dollar-fdo/ .

Levi & Korsinsky is a national firm with offices in New York, New Jersey, and Washington D.C. The firm has extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT: Levi & Korsinsky, LLP Joseph Levi, Esq. Eduard Korsinsky, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (866) 367-6510 www.zlk.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Maxpro Capital Stock Faces Tough Times, Drops to New Lows

Updated Category News Views 87

Maxpro Capital Acquisition Corp. Hits 52-Week Low The current climate in the investment market has led to notable challenges, and Maxpro Capital Acquisition Corp. (APLM) is feeling the strain. With shares dropping to $8.01, the stock has reached a concerning 52-week low. This decline represents a staggering 92.63% decrease over the past year, causing investors to reassess...

Continue Reading
Investors Urged to Join Class Actions Against FLYW, LMT, SOC

Updated Category News Views 133

Important Deadline for Investors in FLYW, LMT, and SOC The Law Offices of Howard G. Smith are highlighting opportunities for investors to engage in class action lawsuits regarding potential securities fraud involving several notable companies, including Flywire Corporation (NASDAQ: FLYW), Lockheed Martin Corporation (NYSE: LMT), and Sable Offshore Corp (NYSE: SOC). For...

Continue Reading
Labcorp's Strong Performance: Q4 2024 and 2025 Outlook

Updated Category News Views 443

Labcorp's Financial Highlights for Q4 2024 Labcorp Holdings Inc. (NYSE: LH), a renowned provider of comprehensive laboratory services, recently released its financial results for the fourth quarter of 2024. The company achieved substantial growth in several key performance areas, reflecting its strategic initiatives in diagnostics and biopharma services. Revenue and...

Continue Reading
In-Depth Analysis of Regeneron Pharmaceuticals' Options Market Trends

Updated Category News Views 204

Insights Into Regeneron Pharmaceuticals' Options Market Recently, there has been a noticeable bullish sentiment among significant investors regarding Regeneron Pharmaceuticals. Investors with substantial resources are making their presence felt in the options market, indicating confidence in the company's future prospects. Upon examining the options trading history for...

Continue Reading
Ant Group Secures $6.5 Billion Credit Line Refinancing Deal

Updated Category News Views 96

Ant Group's Significant Credit Line Refinancing Ant Group, a key player in the fintech sector and closely linked with Alibaba, has revealed plans to refinance a massive credit line amounting to $6.5 billion. This move underscores the company's ongoing financial strategies, particularly under the leadership of its founder, Jack Ma. Refinancing Details This refinancing...

Continue Reading